-
Article
Open AccessCorrection: Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design
-
Article
Open AccessDaratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience
-
Article
Open Access“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience
Belantamab mafodotin is a highly selective targeted therapy for multiple myeloma. It targets the B cell maturation antigen (BCMA) on plasma cells and showed promising results in several randomized clinical tri...
-
Article
Open AccessOutcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design
-
Article
Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma
MV-NIS is an Edmonston lineage oncolytic measles virus expressing the human sodium iodide symporter—a means for monitoring by non-invasive imaging of radioiodine. Patients with relapsed, refractory myeloma who...
-
Article
A phase 1 trial of 90Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma
This phase 1 study (clinical trial NCT00477815) was conducted to determine the maximum tolerated dose (MTD) of yttrium-90 ibritumomab tiuxetan (90Y-Zevalin) with high dose melphalan (HDM) therapy in multiple myel...
-
Article
Open AccessChanges in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma
Little is known about the impact of multiple myeloma (MM) treatment on uninvolved immunoglobulins (Ig). We identified 448 patients who received high-dose dexamethasone (HD-DEX), lenalidomide and dexamethasone ...
-
Article
Open AccessEvolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma
We studied 190 patients with smoldering multiple myeloma (SMM) at our institution between 1973 and 2014. Evolving change in monoclonal protein level (eMP) was defined as ⩾10% increase in serum monoclonal prote...
-
Article
Open AccessPositron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy
We studied 188 patients with a suspected smoldering multiple myeloma (MM) who had undergone a positron emission tomography-computed tomography (PET-CT) scan as part of their clinical evaluation. PET-CT was pos...
-
Article
Open AccessCharacteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma
We studied all patients at our institution with a diagnosis of multiple myeloma (MM), from 1 January 2004 to 1 July 2009, who received lenalidomide–dexamethasone (Rd) as initial therapy and had a time to progr...
-
Article
Erratum: Long-term outcome of patients with multiple myeloma-related advanced renal failure following auto-SCT
Correction to: Bone Marrow Transplantation (2013) 48, 1543–1547; doi:10.1038/bmt.2013.109; published online 5 August 2013 Since the publication of this article the authors have noticed the following errors. ‘M...
-
Article
Open AccessTreatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study
Several cytogenetic abnormalities are associated with poor outcomes in multiple myeloma (MM). We prospectively analyzed the impact of cytogenetic abnormalities on outcomes during the phase 2 PX-171-003-A1 stud...
-
Article
Long-term outcome of patients with mutiple myeloma-related advanced renal failure following auto-SCT
Renal failure commonly complicates multiple myeloma (MM) and is associated with reduced survival. It is not clear whether auto-SCT results in improved renal function or attainment of independence from dialysis...
-
Article
Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapy
-
Article
Predicting PBSC harvest failure using circulating CD34 levels: develo** target-based cutoff points for early intervention
PBSCs are usually mobilized using G-CSF with or without chemotherapy. With the emergence of newer mobilizing agents, predicting poor mobilization may allow early intervention and prevent the costs and complica...
-
Article
Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma
We studied 174 consecutive patients with relapsed refractory multiple myeloma (MM) enrolled on a phase II clinical trial of pomalidomide plus low-dose dexamethasone at Mayo Clinic. Extramedullary disease (EMD)...
-
Article
Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)
Patients with multiple myeloma progressing on current therapies have limited treatment options. Pomalidomide (CC4047), an immunomodulatory drug, has significant activity in relapsed myeloma and previous studie...
-
Article
Myelodysplastic syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma
Long-term survivors after autologous peripheral blood stem cell transplantation (APBSCT) for lymphoma or Hodgkin's disease are known to have a high risk of develo** myelodysplastic syndrome (MDS), but the ri...
-
Article
Influence of preapheresis clinical factors on the efficiency of CD34+ cell collection by large-volume apheresis
We evaluated 120 leukapheresis procedures (93 patients), in order to detect clinical factors that influence the efficiency of CD34+ collection using Cobe Spectra™ cell separators. Hematocrit was >27% and plate...
